Comparison of Carrier and Pathogenic Variants in a Chinese DMD/BMD Cohort.

Front Neurol

Department of Neurology, The First Affiliated Hospital, Sun Yat-sen University, Guangzhou, China.

Published: August 2021


Category Ranking

98%

Total Visits

921

Avg Visit Duration

2 minutes

Citations

20

Article Abstract

Duchenne and Becker muscular dystrophy (DMD/BMD) are X-linked recessively inherited neuromuscular disorders caused by deletions, duplications, or small mutations in the gene. With advances in prenatal diagnosis decreasing the number of affected offspring from carrier mothers, the frequency of variants could increase. Therefore, determining the differences between the carrier and variants of the gene, which are rarely explored, is important for trial planning and genetic diagnosis in the future. A total of 440 patients, 349 of whom had DMD and 91 had BMD, diagnosed in our department between 2012 and 2019, along with their respective mothers, were included in this study. Multiplex ligation-dependent probe amplification was used to detected deletions and duplications in patients and their mothers. Small mutations were detected using next-generation sequencing in the patients, followed by Sanger sequencing in the mothers. Deletions, duplications, and small mutations were identified in 204, 46, and 99 of the 349 patients with DMD and in 50, 10, and 31 of the 91 patients with BMD, respectively. deletions were more concentrated in hotspot regions than carrier deletions of DMD/BMD. No clear bias was observed in the variant distribution between carriers, duplications, and small mutations in DMD/BMD. The carrier frequency of DMD (61.6%) was lower than that of BMD (69.2%), but the difference was not statistically significant. The carrier frequency of deletions of the gene (51.2%) was significantly lower than those of duplications (75%) and small mutations (81.5%). Compared to deletions, deletions from carrier mothers had a wider distribution. Moreover, there was no significant difference between the carrier frequencies of DMD and BMD. Duplications and small mutations were more commonly inherited, while deletions were present .

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8375267PMC
http://dx.doi.org/10.3389/fneur.2021.714677DOI Listing

Publication Analysis

Top Keywords

small mutations
24
duplications small
16
deletions duplications
12
deletions
9
carrier mothers
8
dmd bmd
8
carrier frequency
8
carrier
7
duplications
6
small
6

Similar Publications

Non-small cell lung cancer (NSCLC) is an aggressive malignancy with a poor prognosis. Abnormal expression of focal adhesion kinase (FAK) is closely linked to NSCLC progression, highlighting the need for effective FAK inhibitors in NSCLC treatment. In this study we conducted high-throughput virtual screening combined with cellular assays to identify potential FAK inhibitors for NSCLC treatment.

View Article and Find Full Text PDF

T-cell receptors (TCRs) recognize antigens derived from fragments of somatically expressed proteins that are degraded by the proteasome and presented by specific human leukocyte antigen (HLA) molecules. Recent therapeutic advances using the TCR as a tumor-targeting moiety have focused attention on loss of heterozygosity (LOH) as a potential resistance mechanism. Allele-specific LOH, rather than allele-agnostic, is particularly pertinent, but rarely evaluated.

View Article and Find Full Text PDF

A potent NLRP3 inhibitor effective against both MCC950-sensitive and -resistant inflammation.

Cell Chem Biol

September 2025

Department of Biological Sciences, College of Natural Science, Seoul National University, Seoul 08826, South Korea. Electronic address:

The nucleotide-binding oligomerization domain (NOD)-like receptor protein 3 (NLRP3) inflammasome detects a broad spectrum of pathogen- and damage-associated molecular patterns (PAMPs and DAMPs), initiating inflammatory responses through caspase-1 activation and interleukin (IL)-1β/IL-18 release. Dysregulated NLRP3 activation is implicated in a range of diseases, including infectious diseases, autoinflammatory disorders, metabolic disorders, and cancer, making it an attractive therapeutic target. Here, we identify ZAP-180013 as a potent and selective small-molecule inhibitor of NLRP3 through high-throughput chemical screening.

View Article and Find Full Text PDF

Background: Pheochromocytomas and paragangliomas (PPGLs) are rare catecholamine-secreting neuroendocrine tumors originating from the embryonic neural crest. Approximately 30% of PPGLs are hereditary and are frequently associated with genetic syndromes, including neurofibromatosis type 1 (NF1). Composite PPGLs, which include components of both PPGLs and related tumors such as ganglioneuromas, are extremely rare in NF1 patients.

View Article and Find Full Text PDF